Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants

NCT02243202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: Canagliflozin
DRUG: Phentermine
DRUG: Matching Placebo to Canagliflozin
DRUG: Matching Placebo to Phentermine

Sponsor

Janssen Research & Development, LLC